Effectiveness of Ketorolac Tromethamine in Prevention of Severe Retinopathy of Prematurity
Authors:
- Patrizia PapacciPPPatrizia Papacci
- Velia PurcaroVPVelia Purcaro
- Francesco CotaFCFrancesco Cota
- Mikael Ghennet TesfagabirMTMikael Ghennet Tesfagabir
- Fernando MolleFMFernando Molle
- Domenico LeporeDLDomenico Lepore
- Antonio BaldascinoABAntonio Baldascino
- Costantino RomagnoliCRCostantino Romagnoli
- 1 July 2011
- journal article
- research article
- Published by SLACK, Inc. in Journal of Pediatric Ophthalmology & Strabismus
- Vol. 48 (4) , 247-251
Abstract
Purpose: This study assessed the effectiveness of the use of ketorolac tromethamine to reduce retinopathy of prematurity (ROP) incidence and its progression to more severe forms. Methods: Forty-seven preterm newborn infants with a birth weight (BW) of 1,000 grams or less and/or a gestational age (GA) of 29 weeks or less were enrolled in the study when avascular retina zone I or ROP any stage were diagnosed at screening. Studied infants were randomized to receive ketorolac tromethamine ophthalmic solution in one eye and a drop of placebo in the other eye, until ROP requiring treatment or full retinal vascularization was diagnosed. Results: Only 2 newborn infants did not develop ROP. Among 45 newborn infants who developed ROP, 6 showed different ROP staging between the two eyes, 4 of which had a better outcome in the eye receiving ketorolac tromethamine. The differences between ROP stagings were not significant even when analyzed by GA and BW subgroups. No significant treatment-related side effects occurred. Conclusion: This report suggests that ketorolac tromethamine ophthalmic solution cannot reduce the risk of developing severe ROP in preterm infants. From the Department of Pediatrics (CG, PP, VP, FC, MGT, CM), Division of Neonatology, and the Division of Ophthalmology (FM, DL, AB), Catholic University Sacred Heart, Rome, Italy. The authors have no financial or proprietary interest in the materials presented herein. The authors thank Miss Marta Romagnoli for assistance in preparing and editing the manuscript. Address correspondence to Carmen Giannantonio, MD, Division of Neonatology, Department of Pediatrics, Catholic University Sacred Heart, Largo A. Gemelli, 8, 00168 Rome, Italy. E-mail: carmengiannantonio@libero.it Received: June 15, 2009 Accepted: August 16, 2010 Posted Online: September 22, 2010Keywords
This publication has 29 references indexed in Scilit:
- Lack of Therapeutic Effect of Ranibizumab in Fellow Eyes After Intravitreal AdministrationJournal of Ocular Pharmacology and Therapeutics, 2010
- Pharmacokinetics of Bevacizumab and Its Effect on Vascular Endothelial Growth Factor after Intravitreal Injection of Bevacizumab in Macaque EyesInvestigative Ophthalmology & Visual Science, 2010
- Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: Aqueous drug absorption and prostaglandin E2 levelsJournal of Cataract & Refractive Surgery, 2008
- Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)Ophthalmology, 2007
- Retinopathy of prematurityAngiogenesis, 2007
- Screening Examination of Premature Infants for Retinopathy of PrematurityPediatrics, 2006
- Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic reviewBritish Journal of Ophthalmology, 2005
- Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgeryCurrent Medical Research and Opinion, 2004
- Use of intravenous ketorolac in the neonate and premature babiesPediatric Anesthesia, 2004
- Randomised controlled trial of allopurinol prophylaxis in very preterm infants.Archives of Disease in Childhood - Fetal and Neonatal Edition, 1995